Celecoxib inhibits production of MMP and NO via down-regulation of NF-κB and JNK in a PGE2 independent manner in human articular chondrocytes

Rheumatology International

Volumn 28, Issue 8, 2008, Pages 727-736

  Tsutsumi, R ^a   Ito, H ^a   Hiramitsu, T ^a   Nishitani, K ^a   Akiyoshi, M ^a   Kitaori, T ^a   Yasuda, T ^b   Nakamura, T ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TENRI UNIVERSITY   (Japan)

Author keywords

COX 2 inhibitor; Human articular chondrocyte; MMP 1; MMP 3; Nitric oxide

Indexed keywords

CELECOXIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; INTERLEUKIN 1BETA; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; PROSTAGLANDIN E2; STRESS ACTIVATED PROTEIN KINASE; STROMELYSIN; SYNAPTOPHYSIN;

ARTICLE; CARTILAGE; CARTILAGE CELL; CELL PROTECTION; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME SYNTHESIS; HUMAN; HUMAN CELL; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RHEUMATOID ARTHRITIS;

AGED; CARTILAGE, ARTICULAR; CELLS, CULTURED; CHONDROCYTES; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; DOWN-REGULATION; ENZYME ACTIVATION; HUMANS; INTERLEUKIN-1BETA; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASES; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PHOSPHORYLATION; PYRAZOLES; SULFONAMIDES;

EID: 43449100928     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-007-0511-6     Document Type: Article

References (38)

1. Dieppe PA, Lohmander LS (2005) Pathogenesis and management of pain in osteoarthritis. Lancet 365:965-973
2. Firestein GS (2003) Evolving concepts of rheumatoid arthritis. Nature 423:356-361
3. Mengshol JA, Mix KS, Brinckerhoff CE (2002) Matrix metalloproteinases as therapeutic targets in arthritic diseases: bull's-eye or missing the mark? Arthritis Rheum 46:13-20
4. Tetlow LC, Adlam DJ, Woolley DE (2001) Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage: associations with degenerative changes. Arthritis Rheum 44:585-594
5. Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T (2003) Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 253:269-285
6. Henrotin YE, Bruckner P, Pujol JP (1999) The role of reactive oxygen species in homeostasis and degradation of cartilage. Osteoarthr Cartil 2003 11:747-755
7. Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, Graneto MJ, Lee LF, Malecha JW, Miyashiro JM, Rogers RS, Rogier DJ, Yu SS, Anderson GD, Burton EG, Cogburn JN, Gregory SA, Koboldt CM, Perkins WE, Seibert K, Veenhuizen AW, Zhang YY, Isakson PC (1997) Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benze nesulfonamide (SC-58635, celecoxib). J Med Chem 40:1347-1365
8. Hawkey CJ (1999) COX-2 inhibitors. Lancet 353:307-314
9. Mastbergen SC, Bijlsma JW, Lafeber FP (2005) Selective COX-2 inhibition is favorable to human early and late-stage osteoarthritic cartilage: a human in vitro study. Osteoarthr Cartil 13:519-526
10. Mastbergen SC, Marijnissen AC, Vianen ME, Zoer B, van Roermund PM, Bijlsma JW, Lafeber FP (2006) Inhibition of COX-2 by celecoxib in the canine groove model of osteoarthritis. Rheumatology 45:405-413
11. Mastbergen SC, Jansen NW, Bijlsma JW, Lafeber FP (2006) Differential direct effects of cyclo-oxygenase-1/2 inhibition on proteoglycan turnover of human osteoarthritic cartilage: an in vitro study. Arthritis Res Ther 8:R2
12. El Hajjaji H, Marcelis A, Devogelaer JP, Manicourt DH (2003) Celecoxib has a positive effect on the overall metabolism of hyaluronan and proteoglycans in human osteoarthritic cartilage. J Rheumatol 30:2444-2451
13. Matsuda K, Nakamura S, Matsushita T (2006) Celecoxib inhibits nitric oxide production in chondrocytes of ligament-damaged osteoarthritic rat joints. Rheumatol Int 26:991-995
14. Vincenti MP, Brinckerhoff CE (2002) Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors. Arthritis Res 4:157-164
15. Shaulian E, Karin M (2002) AP-1 as a regulator of cell life and death. Nat Cell Biol 4:E131-E136
16. Chang L, Karin M (2001) Mammalian MAP kinase signalling cascades. Nature 410:37-40
17. Miyamoto M, Ito H, Mukai S, Kobayashi T, Yamamoto H, Kobayashi M, Maruyama T, Akiyama H, Nakamura T (2003) Simultaneous stimulation of EP2 and EP4 is essential to the effect of prostaglandin E2 in chondrocyte differentiation. Osteoarthr Cartil 11:644-652
18. Aoyama T, Liang B, Okamoto T, Matsusaki T, Nishijo K, Ishibe T, Yasura K, Nagayama S, Nakayama T, Nakamura T, Toguchida J (2005) PGE2 signal through EP2 promotes the growth of articular chondrocytes. J Bone Miner Res 20:377-389
19. Nakagawa T, Yasuda T, Hoshikawa H, Shimizu M, Kakinuma T, Chen M, Masaki T, Nakamura T, Sawamura T (2002) LOX-1 expressed in cultured rat chondrocytes mediates oxidized LDL-induced cell death-possible role of dephosphorylation of Akt. Biochem Biophys Res Commun 299:91-97
20. Kleemann RU, Krocker D, Cedraro A, Tuischer J, Duda GN (2005) Altered cartilage mechanics and histology in knee osteoarthritis: relation to clinical assessment (ICRS Grade). Osteoarthr Cartil 13:958-963
21. Yasuda T, Poole AR (2002) A fibronectin fragment induces type II collagen degradation by collagenase through an interleukin-1-mediated pathway. Arthritis Rheum 46:138-148
22. Hiramitsu T, Yasuda T, Ito H, Shimizu M, Julovi SM, Kakinuma T, Akiyoshi M, Yoshida M, Nakamura T (2006) Intercellular adhesion molecule-1 mediates the inhibitory effects of hyaluronan on interleukin-1β-induced matrix metalloproteinase production in rheumatoid synovial fibroblasts via down-regulation of NF-κB and p38. Rheumatology 45:824-832
23. Sadowski T, Steinmeyer J (2001) Minocycline inhibits the production of inducible nitric oxide synthase in articular chondrocytes. J Rheumatol 28:336-340
24. Labarca C, Paigen K (1980) A simple, rapid, and sensitive DNA assay procedure. Anal Biochem 102:344-352
25. Solomon DH, Avorn J, Sturmer T, Glynn RJ, Mogun H, Schneeweiss S (2006) Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. Arthritis Rheum 54:1378-1389
26. Huang WF, Hsiao FY, Tsai YW, Wen YW, Shih YT (2006) Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan : an observational study. Drug Saf 29:261-272
27. Singh G, Fort JG, Goldstein JL, Levy RA, Hanrahan PS, Bello AE, Andrade-Ortega L, Wallemark C, Agrawal NM, Eisen GM, Stenson WF, Ttriadafilopoulos G; SUCCESS-I Investigators (2006) Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med 119:255-266
28. Cha HS, Ahn KS, Jeon CH, Kim J, Koh EM (2004) Inhibitory effect of cyclo-oxygenase-2 inhibitor on the production of matrix metalloproteinases in rheumatoid fibroblast-like synoviocytes. Rheumatol Int 24:207-211
29. Yasuda T, Poole AR (2002) A fibronectin fragment induces type II collagen degradation by collagenase through an interleukin-1-mediated pathway. Arthritis Rheum 46:138-148
30. Yasuda T, Tchetina E, Ohsawa K, Roughley PJ, Wu W, Mousa A, Ionescu M, Pidoux I, Poole AR (2006) Peptides of type II collagen can induce the cleavage of type II collagen and aggrecan in articular cartilage. Matrix Biol 25:419-429
31. Nakamura H, Masuko K, Yudoh K, Kato T, Nishioka K (2007) Effects if celecoxib on human chondrocytes-enchanced production of chemokines. Clin Exp Rheumatol 25:11-16
32. Tegeder I, Pfeilschifter J, Geisslinger G (2001) Cyclooxygenase- independent actions of cyclooxygenase inhibitors. FASEB J 15:2057-2072
33. Zhang X, Morham SG, Langenbach R, Young DA (1999) Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J Exp Med 190:451-459
34. Takada Y, Bhardwaj A, Potdar P, Aggarwal BB (2004) Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene 23:9247-9258
35. Sperandio da Silva GM, Lima LM, Fraga CA, Sant'Anna CM, Barreiro EJ (2005) The molecular basis for coxib inhibition of p38alpha MAP kinase. Bioorg Med Chem Lett 15:3506-3509
36. Steffel J, Hermann M, Greutert H, Gay S, Luscher TF, Ruschitzka F, Tanner FC (2005) Celecoxib decreases endothelial tissue factor expression through inhibition of c-Jun terminal NH2 kinase phosphorylation. Circulation 111:1685-1689
37. Hou CC, Hung SL, Kao SH, Chen TH, Lee HM (2005) Celecoxib induces heme-oxygenase expression in glomerular mesangial cells. Ann N Y Acad Sci 1042:235-245
38. Takahashi T, Ogawa Y, Kitaoka K, Tani T, Uemura Y, Taguchi H, Kobayashi T, Seguchi H, Yamamoto H, Yoshida S (2005) Selective COX-2 inhibitor regulates the MAP kinase signaling pathway in human osteoarthritic chondrocytes after induction of nitric oxide. Int J Mol Med 15:213-219